# The cumulative risk of lung cancer among current, ex- and never-smokers in European men 

A Crispo ${ }^{\text {1,2 }}$, P Brennan ${ }^{*, 2}$, K-H Jöckel ${ }^{3}$, A Schaffrath-Rosario ${ }^{4}$, H-E Wichmann ${ }^{4}$, F Nyberg ${ }^{5}$, L Simonato ${ }^{6}$, F Merletti ${ }^{\mathbf{7}}$, F Forastiere ${ }^{\mathbf{8}}$, P Boffetta $^{2}$ and S Darby ${ }^{9}$<br>${ }^{1}$ Epidemiology Unit, National Cancer Institute, 80131 Naples, Italy; ${ }^{2}$ International Agency for Research on Cancer, 69008 Lyon, France; ${ }^{3}$ Institute for Medical Informatics, Biometry and Epidemiology, 45122 Essen, Germany; ${ }^{4}$ Institute of Epidemiology, GSF National Research Center, 85764 Neuherberg, Germany; ${ }^{5}$ Institute of Environmental Medicine, Karolinska Institute, 17177 Stockholm, Sweden; ${ }^{6}$ Department of Environmental Medicine and Public Health, University of Padova, Italy; ${ }^{7}$ Unit of Cancer Epidemiology, CeRMS and Centre for Oncologic Prevention, University of Turin, 10125 Turin, Italy;<br>${ }^{8}$ Department of Epidemiology, Rome E Health Authority, Rome, Italy; ${ }^{9}$ Clinical Trials Service Unit (CTSU), Radcliffe Infirmary, Oxford OX2 6HE, UK

Recent analyses based on UK data indicate that people who stop smoking, even well into middle age, avoid most of their subsequent risk of lung cancer. We investigated whether similar absolute risks of lung cancer in men are found in other European countries with different smoking patterns and at different stages of their lung cancer epidemic. Using data for men from a multicentre case-control study of lung cancer in the UK, Germany, Italy and Sweden, and including 6523 lung cancer cases and 9468 controls, we combined odds ratio estimates with estimates of national lung cancer incidence rates to calculate the cumulative risk of lung cancer among men by age 75 . Lung cancer cumulative risks by age 75 among continuing smokers were similar for the UK, Germany and Italy at I5.7, I4.3 and $13.8 \%$ respectively, whereas the cumulative risk among Swedish male smokers was $6.6 \%$. The proportion of the risk of lung cancer avoided by quitting smoking before the age of 40 was comparable between the four countries, at $80 \%$ in Italy and $91 \%$ in the UK, Germany and Sweden. Similarly, the proportion of the excess risk avoided by quitting before the age of 50 ranged from $57 \%$ in Italy to $69 \%$ in Germany. Our results support the important conclusion that for long-term smokers, giving up smoking in middle age avoids most of the subsequent risk of lung cancer, and that lung cancer mortality in European men over the next three decades will be determined by the extent to which current smokers can successfully quit smoking.
British Journal of Cancer (2004) 91, I280-1286. doi:I0.1038/sj.bjc. 6602078 www.bjcancer.com
Published online 3 August 2004
© 2004 Cancer Research UK
Keywords: lung cancer; cigarette smoking

Smoking of tobacco products, and in particular of cigarettes, is responsible for most cases of lung cancer in Europe and North America, with an attributable proportion among men in the order of $90 \%$ (Peto et al, 1992; Mannino et al, 2001; Simonato et al, 2001; Jemal et al, 2003). The association between lung cancer and cigarette smoking is strongly related to duration of smoking, and to a lesser extent the amount of tobacco smoked per day, the type of cigarette and other characteristics such as inhalation patterns (Lubin et al, 1984; Boffetta et al, 1999). Measuring precisely the absolute risk of lung cancer for various patterns of smoking (e.g. heavy smokers, long-term ex-smokers) typically requires information on large cohorts with long-term follow-up information. A more efficient, although rarely used, approach (Cornfield, 1951) is to combine measures of odds ratio (OR) from case - control studies with relevant incidence or mortality data. A recent example was based on a case-control study of lung cancer in southwest England including 667 male cases and 2108 male controls (Peto et al, 2000). By incorporating national UK mortality rates for lung cancer in males, the cumulative risk of death from lung cancer by age 75 among current smokers was estimated at $16 \%$, rising to $24 \%$

[^0]for current smokers of at least 25 cigarettes per day. The benefit of quitting smoking was demonstrated with cumulative risks of lung cancer of $10,6,3$ and $2 \%$ for men who stopped smoking at ages 60 , 50,40 and 30 , respectively. It is therefore apparent that smokers who quit, even well into middle age, avoid a large proportion of their subsequent risk of lung cancer. Using a larger multicentre case-control study of lung cancer in Europe, which included the above UK data (Simonato et al, 2001), we investigated whether the absolute risks of lung cancer in men are similar in other European countries with different smoking patterns and in different stages of the lung cancer epidemic.

## MATERIALS AND METHODS

The analysis was based on a multicentre case-control study of lung cancer among men conducted from 1985 to 1994 in the UK, Germany, Italy and Sweden (Jöckel et al, 1998; Nyberg et al, 2000; Peto et al, 2000; Kreienbrock et al, 2001; Fortes et al, 2003; Kreuzer et al, 2003; Richiardi et al, 2004). The UK data formed the basis of the previous absolute risk analysis (Peto et al, 2000). Three centres were in Germany, three in Italy and one each in Sweden and the UK (Table 1). Cases were incident patients with lung cancer aged below 75 years and, for Germany, Italy and Sweden, histologically or cytologically confirmed. Controls were a random sample of the underlying populations selected from local population registers, with the exception of Centre III in Italy, in which controls were

## Risk of lung cancer in European men

A Crispo et al
|28|
Table I Distribution of the study subjects by centre and case-control status

| Centre | Reference ${ }^{\text {a }}$ | Case/control | Region | Source of cases | Source of controls |
| :---: | :---: | :---: | :---: | :---: | :---: |
| UK | Peto et al (2000) | 667/2108 | Southwest England | Residents in Devon and Cornwall | Population registers and patients from hospitals of cases |
| Germany |  |  |  |  | Population registers and random digit dialling |
| Total |  | 3464/3501 |  |  |  |
| Germany I | Jöckel et al (1998) | 805/799 | (I) Bremen, Frankfurt | (I) Residents in Bremen, Frankfurt metropolitan areas |  |
| Germany II | Kreienbrock et al (2001) | 1850/1796 | (II) Parts of NorthrhineWestfalia, Rhineland-Palatine, Saarland, Eastern Bavaria | (II) Residents in parts of Northrhine-Westfalia, Rhineland-Palatine, Saarland, Eastern Bavaria |  |
| Germany III | Kreuzer et al (2003) | 809/906 | (III) Thuringia and Saxony | (III) Residents in Thuringia and Saxony |  |

${ }^{\text {a }}$ Number of subjects included in pooled analysis do not correspond exactly with numbers of subjects in original publications.
selected from patients admitted to the same hospital as the cases for a disease unrelated to smoking. In the UK, a separate hospital control group was also recruited using criteria similar to those in the Italian study. In Sweden, besides the population controls in Stockholm, a second group of mortality-matched controls was selected from among those who died in the same year as the cases but from a nontobacco-related cause of death. For both Sweden and the UK, the distribution of the smoking habits in the two control groups was similar and the results are presented here with the two groups combined.

All subjects who had regularly smoked at least one cigarette per day for at least 1 year ( 6 months in Germany) were considered current or ex-smokers. Current smokers were those who still smoked at interview or had quit less than 2 years previously ( 1 year in the UK), while ex-smokers were those who had quit 2 or 3 years previously. When information on different time periods was available for current smokers, the most recent number of cigarettes smoked was used. Information on other tobacco smoking products was also included after weighting for the amount of tobacco (one pipe $=$ one cigar $=1.5$ cigarillos $=3$ cigarettes $).$ Smokers of only cigars or pipes were excluded from the analysis in the UK data set.

Country-specific relative risks of lung cancer were estimated by means of OR with $95 \%$ confidence intervals using unconditional logistic regression (Breslow and Day, 1980) and adjusting for age. Smoking categories were introduced as dummy variables, and ORs were estimated for each smoking category compared to neversmokers. Overall results for Germany and Italy were calculated by pooling the data from the three centres in each country and adjusting by centre.

The absolute risks were estimated by combining the male agespecific cancer incidence rate in each country with OR for the different smoking categories and the age-specific prevalence of the different smoking habits among study controls (see Appendix A1 for further details). Our assumption was that within each age group the smoking distribution of each national population was represented by our control distribution. Finally, we calculated the cumulative rate ( $C$ ) for the different categories of smoker by adding age-specific absolute rates (in 5-year age groups), and then the cumulative risk by age 75 using the standard formula
( $1-\exp \left(-5 C / 10^{5}\right)$ ) (Breslow and Day, 1987). The cumulative risk may be interpreted as the probability that an individual will develop lung cancer before the age of 75 in the absence of competing causes of death.

National lung cancer incidence rates for the period 1988-1992 were used for the UK and Sweden (Parkin et al, 2003). As national lung cancer incidence rates are not available for Germany and Italy, we estimated these by using the age-specific national lung cancer mortality data corrected by survival rates to obtain an adjusted incidence rate:

$$
\begin{aligned}
\text { incidence rate }= & (\text { national mortality rate } /(1-\text { relative survival } \\
& \text { rate }))
\end{aligned}
$$

Age-specific lung cancer mortality rates were averaged over the period 1988-1994, covering the period when most subjects were recruited. Country-specific lung cancer relative survival data (adjusted for competing causes of death) were obtained from the EUROCARE study (Janssen-Heijnen et al, 1998) covering the period 1985-1994.

95\% confidence intervals for cumulative risks were calculated using floating absolute risks to obtain the variance of the logarithm of OR $\operatorname{Var}(\log r)$ (Easton et al, 1991) and subsequently incorporating a Taylor series expansion. The method of floating absolute risks leads to confidence intervals that are approximately independent and are therefore readily interpreted (Plummer, 2004). Sampling variations in smoking prevalence estimates are not included in the calculation of the confidence intervals, resulting in intervals that may be somewhat too narrow. Further details are given in Appendix A1.

## RESULTS

A total of 6523 cases and 9468 controls have been included in the analysis. The ORs associated with cigarette smoking are presented in Table 2, those for current and ex-smokers being higher in the UK than in the other countries, although this is based on very few (three) lifelong nonsmoking cases in the UK. Cumulative risks for

Table 2 Odds ratios and cumulative risks of lung cancer by age 75, for never-, ex- and current cigarette smokers, among men, by country

| Country | Case/control | OR ${ }^{\text {a }}$ | Standard ${ }^{\text {a }} 95 \%$ CI | Floating ${ }^{\mathbf{b}} \mathbf{9 5 \%} \mathbf{C l}$ | Cumulative risk ${ }^{\mathbf{c}} \mathbf{( 9 5 \% ~ C I )}$ |
| :---: | :---: | :---: | :---: | :---: | :---: |
| UK ${ }^{\text {d }}$ |  |  |  |  |  |
| Nonsmoker | 3/400 | 1.0 |  | 0.3-3.1 | $0.2(0.01-0.4)$ |
| Ex-smoker | 285/1106 | 34.4 | $10.9-107.5$ | 30.2-39.1 | 5.7 (5.0-6.4) |
| Current smoker | 322/453 | 94.8 | 30.2-297.8 | $82.2-109.3$ | 15.7 (14.4-17.0) |
| Germany |  |  |  |  |  |
| Nonsmoker | 63/763 | 1.0 |  | 0.8-1.3 | 0.6 (0.4-0.7) |
| Ex-smoker | 1059/1699 | 7.5 | 5.7-9.8 | 7.0-8.1 | 4.2 (4.0-4.5) |
| Current smoker | 2342/1039 | 27.3 | $20.9-35.6$ | 25.4-29.4 | 14.3 (13.6-15.0) |
| Italy |  |  |  |  |  |
| Nonsmoker | 18/277 | 1.0 |  | 0.6-1.6 | 0.6 (0.3-0.9) |
| Ex-smoker | 520/716 | 11.2 | $6.8-18.2$ | 10.0-12.5 | 6.5 (5.9-7.0) |
| Current smoker | 833/539 | 23.7 | $14.6-38.7$ | $21.3-26.5$ | 13.8 (12.8-14.8) |
| Sweden |  |  |  |  |  |
| Nonsmoker | 36/706 | 1.0 |  | $0.7-1.4$ | 0.4 (0.2-0.5) |
| Ex-smoker | 263/813 | 6.3 | 4.4-9.1 | $5.5-7.3$ | 2.3 (2.0-2.6) |
| Current smoker | 716/805 | 17.4 | $12.3-24.7$ | 15.3-19.3 | 6.6 (6.2-7.0) |

${ }^{\text {a }}$ Odds ratios and $95 \%$ confidence intervals calculated by logistic regression analyses, adjusted for age and centre. ${ }^{\mathrm{b}} 95 \%$ confidence intervals are based on floating variance.
${ }^{\text {c }}$ Cumulative risk expressed as percentage; $95 \%$ confidence intervals are based on floating variance. ${ }^{\text {d }}$ UK estimates of cumulative risk differ slightly from those previously reported (Peto et al, 2000) due to use of incidence instead of mortality data. The OR for ex-smokers and current smokers in UK are also anomalously high by chance, due to the fact that the number of nonsmokers was unusually low by chance. This anomaly will have a minimal effect on the UK cumulative risks for current and ex-smokers. See text for an explanation.
never-smokers are relatively consistent between the four centres, ranging from $0.2 \%$ in the UK to $0.6 \%$ in Italy and Germany. Cumulative risks among ex-smokers were $4.2 \%$ in Germany, $5.7 \%$ in the UK and $6.5 \%$ in Italy, while in current smokers they were $14.3 \%$ in Germany, $15.7 \%$ in the UK and $13.8 \%$ in Italy. In Sweden, however, these cumulative risks were somewhat lower at $2.3 \%$ for ex-smokers and $6.6 \%$ for current smokers.

In Table 3, cumulative risks among ex-smokers are presented after stratifying for age at quitting. For the UK, the cumulative risk of lung cancer by age 75 was $11.1,5.6$ and $2.6 \%$ among men who stopped at around 60,50 and 40 years of age, respectively. For Germany and Italy, the cumulative risks of lung cancer by age 75 among ex-smokers were similar to those obtained for the UK. For Sweden, the cumulative risk by age 75 was $4.2,2.1$ and $0.8 \%$ for those who stopped at around 60, 50 and 40 years of age. These results are presented in further detail in Figure 1, which includes the age-specific cumulative risk in each category of smoking.

The cumulative risks for current smokers according to the number of cigarettes currently smoked per day are presented in Table 4. Among heavy smokers ( $25+$ per day), risks were similar in the UK, Germany and Italy at 23.6, 25.7 and $20.1 \%$ respectively, while in Sweden they were much lower at $12.6 \%$. The pattern among moderate smokers (15-24 per day) was much the same as for heavy smokers, although risks were somewhat lower. For light smokers ( $<5$ per day), risks were similar in Germany and Italy at 2.5 and 1.8, although were higher in the UK and Sweden. This is probably due to the larger amount of cigarettes these 'light' smokers had smoked in the past. For example, over $90 \%$ of the lung cancer cases in the UK who were classified as light smokers had previously smoked over 15 cigarettes per day.

## DISCUSSION

The primary aim of the analysis was to determine whether the absolute risks of developing lung cancer for various groups of smokers in different European countries are similar to those previously reported for the UK (Peto et al, 2000). A high degree of consistency was observed between results for the UK, Germany
and Italy. In all three countries, the cumulative risk of developing lung cancer by age 75 for continuing smokers was around $14-16 \%$, or about one in seven, and the risk for continuing heavy smokers was around $20-25 \%$, or around one in four to one in five. Given that some of these heavy smokers may have been light smokers previously, it is possible that the true cumulative risk for those who have been heavy smokers throughout their adult lives may be even higher. Finally, the relationship between lung cancer risk and quitting smoking was very similar in the UK, Germany and Italy. Overall, the proportion of the excess absolute risk of lung cancer by age 75 compared to never-smokers that was avoided by quitting smoking at age 40 was 85,91 and $80 \%$ in the UK, Germany and Italy respectively. Similarly, the proportion of the excess lung cancer risk avoided by quitting at age 50 was 65,69 and $57 \%$, respectively. A substantially lower cumulative risk was observed in Sweden, with the lifetime risk of current smokers up to age 75 being approximately half that identified in the other three countries. However, the proportion of the excess lung cancer risk avoided by quitting was similar to the other three countries, with 94 and $73 \%$ of the excess risk being avoided by those who quit before age 40 and 50 , respectively.
The heterogeneity of the results from Sweden as compared to the other three countries raises the possibility of bias in our results. However, there is no obvious reason why the cumulative risk in the Swedish study was seriously underestimated. The study recruited a series of incident cases and two control groups, which were subsequently combined: one a group of population controls selected among the Stockholm population alive at the end of the year of recruitment among the cases, and the second a group of controls frequency-matched to cases on vital status at the end of the study period. Individuals who had died of a tobacco-related cause were not included in this second control group (Gustavsson et al, 2000). The Swedish study was restricted to Stockholm county, whereas cumulative risks were calculated based on national incidence rates. We therefore repeated the analysis of the Swedish data using incidence data from Stockholm county. The resulting cumulative risks by age 75 in Stockholm County were $0.4,2.4$ and $6.5 \%$ for never-, ex- and current smokers respectively, which are similar to the figures obtained using national figures.

Table 3 Odds ratios and cumulative risks of lung cancer by age 75, by age at quitting smoking, among men, by country

| Centres | Case/control | OR ${ }^{\text {a }}$ | Standard ${ }^{\text {a }}$ 95\% CI | Floating ${ }^{\text {b }} 95 \% \mathbf{C l}$ | Cumulative risk ${ }^{\text {c ( }} \mathbf{9 5 \%} \mathbf{C l}$ ) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| UK ${ }^{\text {d }}$ |  |  |  |  |  |
| Nonsmoker | 3/400 | 1.0 |  | 0.3-3.1 | $0.2(0.01-0.4)$ |
| $<30$ years | 6/122 | 6.6 | 1.6-26.6 | $2.9-14.9$ | 1.1 (0.3-1.9) |
| 40 years | 12/193 | 8.3 | 2.3-29.7 | 4.6-14.9 | 2.6 (1.3-3.9) |
| 50 years | 44/246 | 23.8 | 7.3-77.6 | $17.3-32.9$ | 5.6 (4.1-7.0) |
| 60 years | 223/545 | 54.6 | 17.3-171.7 | 46.7-63.8 | 11.1 (9.4-12.8) |
| Current smoker | 322/453 | 94.8 | 30.2-297.8 | $82.2-109.3$ | 15.7 (14.4-17.0) |
| Germany |  |  |  |  |  |
| Nonsmoker | 63/763 | 1.0 |  | $0.8-1.3$ | 0.6 (0.4-0.7) |
| $<30$ years | 27/294 | 1.03 | 0.6-1.6 | $0.7-1.5$ | 0.6 (0.3-0.8) |
| 40 years | 52/426 | 2.8 | 1.9-3.9 | $2.2-3.5$ | 1.8 (1.4-2.1) |
| 50 years | 169/498 | 6.8 | 5.0-9.1 | $5.9-7.9$ | $4.9(4.4-5.4)$ |
| 60 years | 804/481 | 15.0 | 11.2-20.1 | $13.0-17.3$ | 10.8 (10.0-11.6) |
| Current smoker | 2342/1039 | 27.3 | 20.9-35.6 | 25.4-29.4 | 14.3 (13.6-15.0) |
| Italy |  |  |  |  |  |
| Nonsmoker | 18/277 | 1.0 |  | 0.6-1.6 | 0.6 (0.3-0.9) |
| $<30$ years | 34/103 | 5.6 | $2.9-10.6$ | 3.6-8.6 | 3.4 (2.0-4.9) |
| 40 years | 61/131 | 4.9 | $2.7-9.0$ | $3.4-7.2$ | 3.3 (2.1-4.4) |
| 50 years | 130/268 | 8.9 | 5.2-15.1 | 7.0-11.3 | 6.3 (5.1-7.5) |
| 60 years | 295/214 | 12.7 | 7.6-21.2 | $10.5-15.4$ | $10.2(9.1-11.2)$ |
| Current smoker | 833/539 | 23.7 | 14.6-38.7 | 21.3-26.5 | 13.8 (12.8-14.8) |
| Sweden |  |  |  |  |  |
| Nonsmoker | 36/706 | 1.0 |  | 0.7-1.4 | $0.4(0.2-0.5)$ |
| <30 years | 4/71 | 1.1 | $0.4-3.2$ | 0.4-3.0 | 0.4 (0.01-0.8) |
| 40 years | 14/158 | 1.7 | $0.9-3.3$ | 1.0-3.0 | 0.8 (0.4-1.1) |
| 50 years | 46/215 | 4.2 | 2.6-6.6 | $3.1-5.8$ | 2.1 (1.6-2.6) |
| 60 years | 199/369 | 7.2 | $4.7-10.9$ | 5.7-9.3 | $4.2(3.6-4.8)$ |
| Current smoker | 716/805 | 17.4 | 12.3-24.7 | 15.3-19.3 | 6.6 (6.2-7.0) |

${ }^{\text {a }}$ Odds ratio and $95 \%$ confidence intervals calculated by logistic regression analyses, adjusted for age and centre. ${ }^{\mathrm{b}} 95 \%$ confidence intervals are based on floating variance.
 UK study.

A further possible explanation is that Swedish men may have started smoking at a later age than in other countries. We therefore repeated the calculation of cumulative risk after stratifying for age at onset of smoking. Among continuing smokers who started smoking before the age of 16 , the cumulative risk of lung cancer by age 75 was $16.5 \%$ in the UK, $20.7 \%$ in Germany, $21.7 \%$ in Italy and $11.5 \%$ in Sweden. Results from such stratified analyses are unstable due to smaller numbers, although they do not indicate that the lower cumulative risks observed in Sweden are fully explained by a later age of onset of smoking. Other possible explanations for the low cumulative lung cancer risk among Swedish men may be different inhalation patterns, smoking of a higher proportion of low-tar cigarettes, and simultaneous use of smokeless tobacco products resulting in a reduced intensity of smoking (Foulds et al, 2003), although no information was collected on these aspects.

The age-standardised mortality rate for lung cancer among Swedish males is substantially lower than in other European countries, at 22.6 per 100000 for the year 2000, while current mortality rates in the UK (48.6), Germany (46.2) and Italy (52.6) are more typical of other European countries (Ferlay et al, 2001). The difference between Sweden and the other countries cannot be explained by differences in consumption. In 1950, consumption of manufactured cigarettes per adult per day was 1.8 in Italy and West Germany, 2.2 in Sweden and 6.0 in the UK (Forey et al, 2002). Separate figures are not available for men and women, although it is likely that the vast majority of cigarettes were smoked by men in all these countries. In Italy and Sweden, consumption subsequently rose steadily after 1950, reaching 6.3 and 4.5 respectively by 1985. In West Germany and the UK, consumption increased from 1950 and peaked in the early 1970s at 7.3 and 8.8 respectively, with subsequent declines to 6.4 and 5.9 respectively by 1985. In all these
countries, the proportion of cigarettes that were smoked by women increased during the period 1950-1985, although to a lesser extent in Italy than elsewhere.

The anomalously high ORs for current and ex-smokers for the UK are attributable to the fact that only three nonsmoking lung cancer cases were found in this study, corresponding to a cumulative risk by age 75 of $0.2 \%$. The majority of the evidence concerning lung cancer risks in lifelong nonsmokers in the UK indicates that they are similar to those seen in the American Cancer Society (ACS) prospective study, corresponding to a cumulative risk by age 75 of around $0.4 \%$ (Peto et al, 1992), suggesting that the low number of nonsmokers observed in the study was a chance finding. In a previous analysis of data from this study in which the ACS data were used for nonsmokers, the ratio of risks in current smokers compared with nonsmokers was estimated to be $100: 3$, that is, about 33.3 (Peto et al, 2000). The same argument would also reduce the ratio of risks in ex-smokers to nonsmokers by a factor of about three. This would suggest that the ORs for current and ex-smokers in the UK are in fact quite compatible with those observed for Germany and Italy.

The anomalously high ORs for the UK have only a minimal effect on the cumulative risks. The reason for this is that the sum of the cumulative risks for all three categories of smokers combined is constrained to be equal to the total cumulative risk as determined by the absolute rate of lung cancer. As the estimated cumulative risk among lifelong nonsmokers in the UK is probably about $0.2 \%$ too low, the sum of the cumulative risks for the other two categories is probably about $0.2 \%$ too high. The cumulative risks for ex-smokers and current smokers in the UK as given in Table 2 are therefore probably each too high by about $0.1 \%$.

## Risk of lung cancer in European men



Figure I Effects of stopping smoking at various ages on the cumulative risk (\%) of death from lung cancer up to age 75 at incidence rate for men in Europe.

Table 4 Odds ratios and cumulative risks of lung cancer by age 75, for current cigarette smokers stratified by amount smoked per day (most recent estimate), among men, by country

| Centres | Case/control | OR ${ }^{\text {a }}$ | Standard ${ }^{\text {a }} 95 \% \mathbf{C l}$ | Floating ${ }^{\mathbf{b}} \mathbf{9 5 \%} \mathbf{C l}$ | Cumulative risk ${ }^{\text {c }}$ (95\% CI) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| UK ${ }^{\text {d }}$ |  |  |  |  |  |
| Nonsmoker |  | 1.0 |  | 0.3-3.1 | $0.2(0.01-0.4)$ |
| $<5$ day-। | 20/44 | 60.6 | 17.3-212.0 | $35.7-102.8$ | 10.4 (5.8-14.8) |
| 5-14 day-1 | 108/179 | 80.9 | 25.2-256.7 | 63.3-102.1 | 13.1 (11.2-16.0) |
| 15-24 day ${ }^{-1}$ | 126/169 | 99.4 | $31.2-316.7$ | 78.9-125.2 | 16.5 (13.7-19.2) |
| $25+$ day $^{-1}$ | 68/61 | 148.6 | 45.3-487.0 | 105.2 -210.0 | 23.6 (17.5-29.3) |
| Germany |  |  |  |  |  |
| Nonsmoker | 63/763 | 1.0 |  | 0.8-1.3 | 0.6 (0.4-0.7) |
| $<5$ day $^{-1}$ | 28/91 | 4.5 | 2.4-8.4 | 2.5-8.0 | 2.5(2.1-3.0) |
| 5-14 day ${ }^{-1}$ | 576/412 | 17.6 | 13.1-23.6 | $15.3-20.3$ | $9.5(9.0-10.1)$ |
| 15-24 day ${ }^{-1}$ | $1171 / 385$ | 33.6 | 25.3-44.5 | 29.9-37.8 | 17.4 (16.6-18.2) |
| $25+$ day $^{-1}$ | 567/147 | 52.2 | 37.7-73.2 | 42.8-63.6 | 25.7 (24.3-27.0) |
| Italy |  |  |  |  |  |
| Nonsmoker | 18/277 | 1.0 |  | 0.6-1.6 | 0.6 (0.3-0.9) |
| $<5$ day $^{-1}$ | 10/32 | 3.0 | 1.1-8.1 | 1.2-7.1 | 1.8 (1.4-2.3) |
| 5-14 day ${ }^{-1}$ | 206/202 | 13.9 | 8.2-22.4 | 11.3-17.1 | 8.3 (7.6-9.0) |
| $15-24 \text { day }^{-1}$ | 395/208 | $26.8$ | $16.1-44.5$ | 22.5-31.9 | $15.4(14.4-16.4)$ |
| $25+$ day $^{-1}$ | 222/97 | 35.9 | $21.0-61.4$ | 28.0-46.0 | 20.1 (18.6-21.5) |
| Sweden |  |  |  |  |  |
| Nonsmoker | 36/706 | 1.0 |  | $0.7-1.4$ | $0.4(0.2-0.5)$ |
| $<5$ day $^{-1}$ | 14/14 | 19.6 | 8.7-44.2 | $9.3-41.1$ | 7.0 (4.8-9.2) |
| 5-14 day ${ }^{-1}$ | 193/346 | 10.9 | 7.5-15.9 | $9.2-13.0$ | 4.0 (3.6-4.3) |
| 15-24 day ${ }^{-1}$ | 320/325 | 19.3 | 13.3-27.9 | $16.5-22.5$ | $6.9(6.5-7.4)$ |
| $25+$ day $^{-1}$ | 189/79 | 36.2 | 23.5-55.8 | 27.6-47.7 | 12.6 (11.3-13.9) |

${ }^{\text {a }}$ Odds ratios and $95 \%$ confidence intervals calculated by logistic regression analyses, adjusted for age and centre. ${ }^{\mathrm{b}} 95 \%$ confidence intervals are based on floating variance.
 these cases, $93 \%$ had smoked over 15 day $^{-1}$ in the past, and several had smoked over 30.

The present study was restricted to lung cancer, although, considering its implications, it is noteworthy that a comparably large benefit of stopping smoking was found for all-cause mortality in the prospective study among British doctors (Doll et al, 1994). In a recent review of smoking-related mortality in developed countries (Peto et al, 2003), it has been estimated that during the year 2000 in the 15 countries, then members of the European Union, there were 172000 smoking-attributed male deaths at ages 35-69, comprising $29 \%$ of all male deaths in this age range, while for all ages the corresponding figures were 398000 and $22 \%$. In the 10 new member states of the European Union, the proportion of deaths attributable to smoking is even higher. It is estimated that, in 2000, 37\% of all male deaths at ages 35-69 and $28 \%$ of all male deaths were attributable to smoking, corresponding to 73000 deaths at ages $35-39$ and 113000 at all ages. The estimates of cumulative risk obtained in the present study reinforce the conclusion that, for people who have been smoking for many years, giving up smoking in middle age
means avoiding most of the subsequent risk of developing lung cancer or of dying from a tobacco-related disease. This result has major public health implications. Tobacco-related mortality in Europe over the next three decades will be determined by the extent to which current smokers can be persuaded to quit smoking.

## ACKNOWLEDGEMENTS

Anna Crispo worked on this study under the tenure of a Special Training Award from the International Agency for Research on Cancer. Fredrik Nyberg is currently employed by AstraZeneca. AstraZeneca has not contributed any direct financing to this study.

The study was partially supported by the Italian Association for Cancer Research (AIRC), MURST and Special Project 'Oncology', Compagnia di San Paolo FIRMS.

## REFERENCES

Boffetta P, Pershagen G, Jöckel KH, Forastiere F, Gaborieau V, Heinrich J, Jahn I, Kreuzer M, Merletti F, Nyberg F, Rösch F, Simonato L (1999) Cigar and pipe smoking and lung cancer risk: a multicenter study from Europe. J Natl Cancer Inst 91: 697-701
Breslow NE, Day NE (1980) Statistical Methods in Cancer Research, Vol I. The Analysis of Case-Control Studies (IARC Scientific Publications No. 32). Lyon: International Agency for Research on Cancer

Breslow NE, Day NE (1987) Statistical Methods in Cancer Research, Vol II. The Design and Analysis of Cohort Studies (IARC Scientific Publications No. 82). Lyon: International Agency for Research on Cancer

Cornfield J (1951) A method for estimating comparative rates from clinical data; applications to cancer of the lung, breast, and cervix. J Natl Cancer Inst 11: 1269-1275
Doll R, Peto R, Wheatley K, Gray R, Sutherland I (1994) Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 309: 901-911
Easton DF, Peto J, Babiker AG (1991) Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat Med 10: 1025-1035

Ferlay J, Bray F, Pisani P, Parkin DM (2001) GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0 (IARC CancerBase No. 5). Lyon: International Agency for Research on Cancer
Forey B, Hamling J, Lee P, Wald N (2002) International Smoking Statistics. Oxford: Oxford University Press
Fortes C, Forastiere F, Farchi S, Mallone S, Trequattrinni T, Anatra F, Schmid G, Perucci CA (2003) The protective effect of the Mediterranean diet on lung cancer. Nutr Cancer 46: 30-37
Foulds J, Ramstrom L, Burke M, Fagerstrom K (2003) Effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tob Control 12: 349-359
Gustavsson P, Jakobsson R, Nyberg F, Pershagen G, Jarup L, Scheele P (2000) Occupational exposure and lung cancer risk: a population-based case-referent study in Sweden. Am J Epidemiol 152: 32-40
Janssen-Heijnen ML, Gatta G, Forman D, Capocaccia R, Coebergh JW (1998) Variation in survival of patients with lung cancer in Europe, 1985-1989. Eur J Cancer 34: 2191-2196
Jemal A, Travis WD, Tarone RE, Travis L, Devesa SS (2003) Lung cancer rates convergence in young men and women in the United States: analysis by birth cohort and histologic type. Int J Cancer 105: 101-107
Jöckel KH, Ahrens W, Jahn I, Pohlabeln H, Bolm-Audorff U (1998) Occupational risk factors for lung cancer: a case - control study in West Germany. Int J Epidemiol 27: 549-560
Kreienbrock L, Kreuzer M, Gerken M, Dingerkus G, Wellmann J, Keller G, Wichmann HE (2001) Case - control study on lung cancer and residential radon in western Germany. Am J Epidemiol 153: 42-52
Kreuzer M, Heinrich J, Wolke G, Schaffrath Rosario A, Gerken M, Wellmann J, Keller G, Kreienbrock L, Wichmann HE (2003) Residential radon and risk of lung cancer in Eastern Germany. Epidemiology 14: 559-568
Lubin JH, Blot WJ, Berrino F, Flamant R, Gillis CR, Kunze M, Schmahl D, Visco G (1984) Patterns of lung cancer risk according to type of cigarette smoked. Int J Cancer 33: 569-576

## Appendix A1

The cumulative risk was calculated using methods similar to those described by Peto et al (2000). The following box summarises the main measures used to obtain the cumulative risk:

## $r_{i}$ is the relative risk in the $i_{i}$ th smoking category

where the smoking categories are: I = never-smokers, 2 = ex-
smokers (subdivided in some analyses by age at which they quit smoking ( $<30,30-40-, 50-, 60+$ ), $3=$ current smokers subdivided in some analyses by number of cigarettes per day ( $<5$, 5-14, 15-24, 25+)
$p_{i j}$ is the percentage of the controls in the jth age group and the ith
smoking category
where the age categories are 35-39, 40-44, 45-49, 50-54,
$55-59,60-64,65-69$ and $70-74$ years
$S_{j}=r_{1} p_{1 j}+\cdots+r_{1} p_{i j}$
$h_{j}$ is the age-specific incidence rate
$f_{j}=h_{j} /\left(S_{1}+\cdots+S_{j}\right)$
$a_{i j}$ is the absolute rate in the $(i, j)$ th cell, and $a_{i j}=\left(f_{r_{i}}\right)$
$C_{i}$ is the cumulative rate, and $C_{i}=\sum_{j} R_{j} a_{i j}$
where $R_{j}$ is the width of the $j$ th age category in years
cumulative risk $(\%)=100\left(1-\exp \left(-C_{i}\right)\right)$

Mannino DM, Ford E, Giovino GA, Thun M (2001) Lung cancer mortality rates in birth cohorts in the United States from 1960 to 1994. Lung Cancer 31: 91-99
Nyberg F, Gustavsson P, Jarup L, Bellander T, Berglind N, Jakobsson R, Pershagen G (2000) Urban air pollution and lung cancer in Stockholm. Epidemiology 11: 487-495
Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J (2003) Cancer Incidence in Five Continents, Vol VII (IARC Scientific Publications No. 143). Lyon: International Agency for Research on Cancer

Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R (2000) Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 321: 323-329
Peto R, Lopez AD, Boreham J, Thun M (2003) Mortality from Smoking in Developed Countries 1950-2000, 2nd edn, http://www.ctsu.ox.ac.uk/ $\sim$ tobacco/ (data updated 15th July 2003 and last viewed 15th March 2004)

Peto R, Lopez AD, Boreham J, Thun M, Heath Jr C (1992) Mortality from tobacco in developed countries: indirect estimation from national vital statistics. Lancet 339: 1268-1278
Plummer M (2004) Improved estimates of floating absolute risk. Stat Med 23: 93-104
Richiardi L, Boffetta P, Simonato L, Forastiere F, Zambon P, Fortes C, Gaborieau V, Merletti F (2004) Occupational risk factors for lung cancer in men and women: a population based case-control study in Italy. Cancer Causes Control 15: 285-294
Simonato L, Agudo A, Ahrens W, Benhamou E, Benhamou S, Boffetta P, Brennan P, Darby SC, Forastiere F, Fortes C, Gaborieau V, Gerken M, Gonzales CA, Jöckel KH, Kreuzer M, Merletti F, Nyberg F, Pershagen G, Pohlabeln H, Rösch F, Whitley E, Wichmann HE, Zambon P (2001) Lung cancer and cigarette smoking in Europe: an update of risk estimates and an assessment of inter-country heterogeneity. Int J Cancer 91: 876-887

Briefly, to estimate the cumulative risk, first we need to calculate the relative risks in the various smoking categories (1). In our study, the relative risks of lung cancer were estimated by means of OR using unconditional logistic regression, and lifelong nonsmokers formed the reference category.
The second step was to calculate the percentage of controls in each smoking category and for each age group (2) using the assumption that within each country the smoking distribution of the population was represented by the smoking distribution observed among the study controls.
The third step was the estimation of common factors combining the relative risk (1) for the different smoking categories with the age-specific prevalence of such smoking habits among study controls (2), thus obtaining the quantities denoted by (3).

Combining the age-specific cancer incidence rates of each country (4) with the common factors (3), we obtained the proportions given in (5). Multiplying these proportions with the relative risks for the different smoking categories produced the age-specific absolute risks in the different smoking categories (6).

Next we calculated the cumulative rates (7) for the different categories of smoker by adding age-specific absolute rates, and then finally the cumulative risks by age 75 were estimated using the standard formula (8). The cumulative risk may be interpreted as the probability that an individual will develop lung cancer before age 75 in the absence of competing causes of death.


[^0]:    *Correspondence: Dr P Brennan, Gene-Environment Epidemiology Group, International Agency for Research on Cancer, 150 cours Albert-Thomas, 69008 Lyon, France; E-mail: brennan@iarc.fr
    Received 24 March 2004; revised 21 June 2004; accepted 21 June 2004; published online 3 August 2004

